USPTO Patent Grant: Benzylamine Derivative for Anti-Tumor Efficacy
Summary
The USPTO has granted a patent (US12583822B2) to the Academy of Military Medical Sciences for a benzylamine derivative with potential anti-tumor efficacy. The patent covers the derivative, its preparation method, and its use in treating PD-1/PD-L1-related diseases.
What changed
The United States Patent and Trademark Office (USPTO) has issued patent US12583822B2 for a novel benzylamine derivative. The patent, assigned to the Academy of Military Medical Sciences, details the compound's structure, a method for its preparation, and its application in treating diseases related to PD-1/PD-L1 interaction, citing significant in vivo anti-tumor efficacy.
This patent grant signifies the protection of intellectual property for a specific pharmaceutical compound. While it does not impose direct compliance obligations on other entities, it is relevant for drug manufacturers and pharmaceutical companies involved in oncology research and development, particularly those working with immunotherapy targets like PD-1/PD-L1. Companies operating in this space should be aware of this granted patent to avoid potential infringement issues.
Archived snapshot
Mar 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Benzylamine derivative, preparation method therefor and use thereof
Grant US12583822B2 Kind: B2 Mar 24, 2026
Assignee
Academy of Military Medical Sciences
Inventors
Junhai Xiao, Song Li, Jialin Guo, Wu Zhong, Longlong Luo, Zhibing Zheng, Xinbo Zhou, Xingzhou Li, Ruiyuan Cao, Shiyong Fan, Dian Xiao, Fei Xie, Wei Li
Abstract
The present invention relates to a benzylamine derivative, a preparation method therefor and use thereof, and in particular, to a benzylamine derivative as represented by general formula (I), or a pharmaceutically acceptable stereoisomer, salt, solvate or prodrug thereof, which has a strong binding capability with human PD-L1, can obviously inhibit the interaction of PD-1/PD-L1, and has significant anti-tumor efficacy in vivo. Therefore, the present invention also relates to a preparation method for the benzylamine derivative and use thereof in preparing a drug for treating PD-1/PD-L1-related diseases.
CPC Classifications
C07D 213/85
Filing Date
2021-07-28
Application No.
18020923
Claims
12
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.